Literature DB >> 11245723

Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy.

S Misawa1, S Kuwabara, M Mori, N Kawaguchi, Y Yoshiyama, T Hattori.   

Abstract

BACKGROUND: Activated macrophages and T lymphocytes may play a role in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). Both cell types secrete tumor necrosis factor-alpha (TNFalpha), which has toxic effects on myelin and endothelial cells.
METHODS: The serum concentration of TNFalpha was measured by ELISA and compared with clinical and electrophysiological profiles in 20 patients with CIDP.
RESULTS: An increased serum level of TNFalpha was detected in 5 (25%) patients and was associated with subacute progression, severe neurologic disabilities, and symmetric weakness involving proximal as well as distal muscles. TNFalpha levels increased during the active phase in this subgroup of patients. The levels of TNFalpha correlated with the severity of demyelinating conduction abnormalities in the intermediate as well as distal nerve segments, suggesting demyelination diffusely distributed along the nerves.
CONCLUSION: Circulating TNFalpha increases during the active phase in a subgroup of CIDP patients and may play a role in the pathogenesis of demyelination and the breakdown of the blood-nerve barrier in CIDP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245723     DOI: 10.1212/wnl.56.5.666

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.

Authors:  S Kuwabara; S Misawa; M Mori; N Tamura; M Kubota; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 4.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

Review 5.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Inna Kleyman; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 6.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

7.  Differential gene expression of cytokines and neurotrophic factors in nerve and skin of patients with peripheral neuropathies.

Authors:  Nurcan Üçeyler; Nadja Riediger; Waldemar Kafke; Claudia Sommer
Journal:  J Neurol       Date:  2014-11-05       Impact factor: 4.849

8.  Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency.

Authors:  Xiaopei L Zeng; Anil Nagavalli; Colin-Jamal Smith; James F Howard; Maureen A Su
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

9.  Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy.

Authors:  A Chiò; D Cocito; E Bottacchi; C Buffa; M Leone; F Plano; R Mutani; A Calvo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-10       Impact factor: 10.154

Review 10.  Status of immune mediators in painful neuropathies.

Authors:  Nurcan Uçeyler; Claudia Sommer
Journal:  Curr Pain Headache Rep       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.